Pre-clinical biotechnology company developing small-molecule therapies for neurodegenerative disorders
Pre-clinical biotechnology company developing small-molecule therapies for neurodegenerative disorders. Its research focuses on inhibiting SIRT2, a protein associated with Parkinson’s and Huntington’s disease, with the goal of addressing protein misfolding and cellular stress to develop disease-modifying treatments.